Clinical trial

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

NCT02277457

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2015-09-01

PhaseEARLY_PHASE1

Study timeline

Study start (unknown)2015-09-01Date precision: month

Registry last updated2016-06-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancerunresolved

Interventions

PET-Adaptive RTRADIATION

ErlotinibDRUG · verified · RxNorm: erlotinib

CrizotinibDRUG · verified · RxNorm: crizotinib

Sponsors & collaborators

University of Michigan Rogel Cancer Centerlead sponsor

Augusta Universitycollaborator

Mapped research locations

Ann ArborMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02277457 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.